Published : 21 Dec 2012
Today a Dutch biotechnology company appointed Aagami for its out-licensing and partnering needs in India. The company is building a pipeline of innovative human bispecific antibodies and single cell-derived combinations of antibodies for cancer therapy.
Through the use of a common antibody light chain and CH3 heterodimerization technology, these full length IgG antibody therapeutics can be robustly produced at high yields from a single clonal manufacturing cell line using standard approaches.
The company discovers and develops innovative therapeutic human multispecific antibodoes with improved clinical efficacy based on common light chain antibody technologies. With the discovery scene hotting up in India and more and more Indian companies engaging in innovative biotech work Aagami feels confident to find appropriate partners for co-development and licensing this innvative Dutch companies technologies and products in development.